Viewing Study NCT04317469



Ignite Creation Date: 2024-05-06 @ 2:24 PM
Last Modification Date: 2024-10-26 @ 1:31 PM
Study NCT ID: NCT04317469
Status: UNKNOWN
Last Update Posted: 2020-03-23
First Post: 2020-03-18

Brief Title: Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome ARDS in Comparison to Interleukin 6 IL-6
Sponsor: Ain Shams University
Organization: Ain Shams University

Study Overview

Official Title: Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome ARDS in Comparison to Interleukin 6 IL-6
Status: UNKNOWN
Status Verified Date: 2020-03
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In this prospective study of 60patients we tested the hypothesis That markedly elevated levels of plasma von Willebrand factor VWF a marker of endothelial cell injury might predict the development of acute respiratory distress syndrome ARDS in risky patients We compared our result to IL6 as control biomarker for ARDS development

Acute lung injury was quantified on two -point scoring system Berlin definition of ARDS and Murray score of acute lung injury

Plasma levels of both vWF and IL6 were be measured on T0 ie at start of the study once the patient considered to be risky for ARDS development to obtain their baseline levels T48 after 48 hours and T72 after 72 hours
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None